Skip Navigation
Skip to contents
Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

16 results
Display

Correspondence on Letter regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”

Yeo YH, Yang JD

CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Recent updates on pharmacologic therapy in non-alcoholic fatty liver disease

Chang Y, Jeong SW, Jang JY

CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Changing from NAFLD to MASLD: Similar cumulative incidence of reflux esophagitis between NAFLD and MASLD

Fukunaga S, Mukasa M, Nakano D, Tsutsumi T, Kawaguchi T

CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Letter regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”

Daungsupawong H, Wiwanitkit V

CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Letter regarding “Waiting for the changes after the adoption of steatotic liver disease”

Yew KC, Wong SH, Wong VWS, Oon HH

CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Correspondence on Letter regarding “Waiting for the changes after the adoption of steatotic liver disease”

Yoon EL, Jun DW

CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Letter regarding “Treated chronic hepatitis B is a good prognostic factor of diffuse large B-cell lymphoma”

Hsiao C, Liaw YP

CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Letter 2 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”

Zhang Y, Wu L, Mu Z, Ren L, Chen Y, Liu H, Xu L, Wang Y, Wang Y, Cheng S, Tham YC, Sheng B, Wong TY, Ji H

CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Erratum to ‘Correspondence on Letter regarding “Evidencebased hyponatremia management in liver disease”’ [Clin Mol Hepatol 2023;29:1048-1049]

Baek SH, Ryu JY, Kim S

CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Recent advances in the management of hepatocellular carcinoma

Sankar K, Gong J, Osipov A, Miles SA, Kosari K, Nissen NN, Hendifar AE, Koltsova EK, Yang JD

Liver cancer remains a challenge of global health, being the 4th leading cause of cancer death worldwide. Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation

Tsai YN, Wu JL, Tseng CH, Chen TH, Wu YL, Chen CC, Fang YJ, Yang TH, Nguyen MH, Lin JT, Hsu YC

Background/Aims: Finite nucleos(t)ide analog (NA) therapy has been proposed as an alternative treatment strategy for chronic hepatitis B (CHB), but biomarkers for post-treatment monitoring are limited. We investigated whether measuring...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Taiwan Association for the Study of the Liver-Taiwan Society of Cardiology Taiwan position statement for the management of metabolic dysfunction- associated fatty liver disease and cardiovascular diseases

Cheng PN, Chen WJ, Hou CJY, Lin CL, Chang ML, Wang CC, Chang WT, Wang CY, Lin CY, Hung CL, Peng CY, Yu ML, Chao TH, Huang JF, Huang YH, Chen CY, Chiang CE, Lin HC, Li YH, Lin TH, Kao JH, Wang TD, Liu PY, Wu YW, Liu CJ

Metabolic dysfunction-associated fatty liver disease (MAFLD) is an increasingly common liver disease worldwide. MAFLD is diagnosed based on the presence of steatosis on images, histological findings, or serum marker levels...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide

Hong H, Choi WM, Lee D, Shim JH, Kim KM, Lim YS, Lee HC, Choi J

Background/Aims: Tenofovir disoproxil fumarate (TDF) is known to have a lipid-lowering effect. This is in contrast to tenofovir alafenamide (TAF), which has a lipid-neutral effect. Therefore, concerns have been raised...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Comparison of four histological scoring systems for autoimmune hepatitis to improve diagnostic sensitivity

Ahn S, Jeong SH, Cho EJ, Lee K, Kim G, Kim H

Background/Aims: The histological criteria in the 1999 and 2008 scoring systems proposed by the International Autoimmune Hepatitis Group (IAIHG) have their inherent limitations in diagnosing autoimmune hepatitis (AIH). In this...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Artificial intelligence predicts direct-acting antivirals failure among hepatitis C virus patients: A nationwide hepatitis C virus registry program

Lu MY, Huang CF, Hung CH, Tai C, Mo LR, Kuo HT, Tseng KC, Lo CC, Bair MJ, Wang SJ, Huang JF, Yeh ML, Chen CT, Tsai MC, Huang CW, Lee PL, Yang TH, Huang YH, Chong LW, Chen CL, Yang CC, Yang S, Cheng PN, Hsieh TY, Hu JT, Wu WC, Cheng CY, Chen GY, Zhou GX, Tsai WL, Kao CN, Lin CL, Wang CC, Lin TY, Lin C, Su WW, Lee TH, Chang TS, Liu CJ, Dai CY, Kao JH, Lin HC, Chuang WL, Peng CY, Tsai CW, Chen CY, Yu ML, TACR Study Group

Background/Aims: Despite the high efficacy of direct-acting antivirals (DAAs), approximately 1–3% of hepatitis C virus (HCV) patients fail to achieve a sustained virological response. We conducted a nationwide study to...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Protein-centric omics analysis reveals circulating complements linked to non-viral liver diseases as potential therapeutic targets

Shi Y, Dong H, Sun S, Wu X, Fang J, Zhao J, Han J, Li Z, Wu H, Liu L, Wu W, Tian Y, Yuan G, Fan X, Xu C

Background/Aims: To evaluate the causal correlation between complement components and non-viral liver diseases and their potential use as druggable targets. Methods: We conducted Mendelian randomization (MR) to assess the causal role...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr